A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Interventions: DRUG: LEE011|DRUG: Letrozole|DRUG: Tamoxifen|DRUG: Fulvestrant|DRUG: goserelin
Sponsor: Novartis Pharmaceuticals